Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
1348 results
D3.179 - Longitudinal breath profiling of exhaled volatile organic compounds differentiates viral-induced asthma exacerbation from clinical control
D3.183 - Determination of IgE antibodies against recombinant allergens (Phl p 1 and Phl p 5) in a random sample of patients from Madrid with pollinosis before and after one year of subcutaneous immunotherapy
D3.184 - Comparative immunogenicity of mixed versus individual extracts from the storage mites Acarus siro and Tyrophagus putrescentiae
D3.185 - Clinical Characteristics of Patients with Hymenoptera Venom Allergy Treated with Venom Immunotherapy: A Retrospective Study
D3.187 - Sustained Clinical Benefit of Allergen Immunotherapy in Allergic Rhinitis: A Real-Life Study
D3.188 - Real-Life Effectiveness of Subcutaneous Allergen Immunotherapy Assessed by Medication Consumption: A Retrospective Cohort Study
D3.190 - Protocol for a real-world Study to Track Response to Oralair in Naïve patients with Grass pollen allergy (STRONG) in the Netherlands
D3.191 - Demonstrating the Stability of Allergoids, the Next Generation of Allergen Therapy
D3.192 - Safety of AIT with Depigmented-polymerized extracts in patients with severe allergic asthma. A subanalysis of the SAGITAL study
D3.195 - Building expert consensus on the positioning of allergen immunotherapy (AIT) within a treatment paradigm for allergic rhinitis/rhinoconjunctivitis led by disease remission: A Delphi consensus
D3.196 - Safety of subcutaneous immunotherapy with purified native protein Cup a 1, a major allergen of Cupressus arizonica: 6-year real-world data
D3.198 - Challenges of using clinical scores as primary endpoints in allergology trials
D3.199 - Severe systemic allergic reaction following violation of elimination diet in a patient with sensitization despite achieved remission on allergen-specific immunotherapy
D3.200 - Broad profile of olive pollen sensitisation as a key factor in immunotherapy failure
D3.201 - Subcutaneous immunotherapy with a depigmented cat allergoid is safe in patients with cat allergy and beneficial for mental health in adolescents
D3.202 - Characterising relevant major allergens beyond modification: from allergen to allergoid
D3.203 - Characterisation of relevant allergens in grass pollen extracts
D3.205 - Two-year Outcomes of Multiple Low-Dose Oral Immunotherapies for combination of Tree Nuts or Peanut for Severe Allergy Patients
D3.206 - Pollen-Food Allergy Syndrome (PFAS): A New Paradigm in Allergy Practice – Results of a Survey Among Allergists
D3.207 - Symptomatology and Sensitization Profiles of Patients Undergoing Subcutaneous Immunotherapy for Aeroallergens in Greece
Pagination
First page
First
Previous page
Previous
…
Page
57
Page
58
Page
59
Page
60
Current page
61
Page
62
Page
63
Page
64
Page
65
…
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download